Search
Dexamethasone Treatment Options
A collection of 1456 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
325 - 336 of 1456
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
Completed
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Hawaii MU NCORP, Honolulu, Hawaii +17 locations
Conditions: Breast Carcinoma
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Active Not Recruiting
In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma. Specifically, the objective of this trial is to determine if, in the era of novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple myeloma in younger patients. In this stu... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/17/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +45 locations
Conditions: Multiple Myeloma
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
Recruiting
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
12/17/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Active Not Recruiting
Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT.
Pomalidomide is active against MM cells refractory to both bortezomib and lenalidomide, making it an ideal choice for continuation therapy following second ASCT. Adding elotuzumab may increase efficacy and also the durab... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/16/2024
Locations: Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado +2 locations
Conditions: Multiple Myeloma in Relapse
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Active Not Recruiting
This study will evaluate the feasibility of combining four of the most active agents available for the treatment of multiple myeloma. Further the investigators will attempt to assess the activity of this combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
Recruiting
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco, California +18 locations
Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
Completed
The goal of this clinical research study is to learn if light electrical stimulation to the wrist area during surgery is feasible in women having breast surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Post-Operative Nausea and Vomiting, Breast Cancer
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Recruiting
This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/11/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Active Not Recruiting
This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).
All eligible subjects must be previously treated with at least 3 prior regimens including lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be refractory to their last line of therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Local Institution - 103, Duarte, California +53 locations
Conditions: Multiple Myeloma
DARA RVD For High Risk SMM
Active Not Recruiting
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma.
The names of the study drugs involved in this study are:
* Daratumumab (also called Darzalex Faspro)
* Bortezomib (also called Velcade)
* Lenalidomide (also called Revlimid)
* Dexamethasone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2024
Locations: Stamford Hospital, Stamford, Connecticut +5 locations
Conditions: High-risk Smoldering Multiple Myeloma, Multiple Myeloma
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Arizona Clinical Research Center - Hunt - PPDS, Tucson, Arizona +53 locations
Conditions: Solid Tumor
Individualizing Corticosteroid Use in Pneumonia
Recruiting
In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Pneumonia
325 - 336 of 1456